Exercise Resistance in Type 2 Diabetes (NCT01911104) | Clinical Trial Compass
Active — Not RecruitingNot Applicable
Exercise Resistance in Type 2 Diabetes
United States84 participantsStarted 2013-10-31
Plain-language summary
The purpose of this study is to collect data to help researchers identify factors that prevent certain individuals from receiving the beneficial effects of exercise.
Who can participate
Age range30 Years – 65 Years
SexALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Type 2 Diabetes Inclusion Criteria (Group 1)
* Age 30 to 65 years.
* Male and Female
* Type 2 diabetes determined by self-report or by a fasting glucose \> 126mg/dl
* POCT HbA1c result is 5.7-8.8% or for those on anti-diabetic medications, POCT HbA1c \< 8.9% (no lower limit defined to account for those who illustrate tight glycemic control due to anti-diabetic medications).
* HbA1c between 6.0% and 8.5% or for those on anti-diabetic medications, HbA1c ≤ 8.5% (no lower limit defined to account for those who illustrate tight glycemic control due to anti-diabetic medications). If a participant misses the screening HbA1c by a small margin (HbA1c ± 0.1%), the HbA1c can be repeated once.
* Not involved in regular exercise program
* Willing to exercise every day for the study period
* If applicable, those currently taking anti-diabetic medication are taking metformin, a sulfonylurea, DPP IV inhibitor, alpha-glucosidase inhibitor, a meglitinide, colesevelam, cycloset or a SGLT2 inhibitor. Those taking 2 of these medications may proceed.
* If applicable, willing to cease anti-diabetic medication use for the duration of the intervention.
* BMI ≥ 22 kg/m2
Young Athletes Inclusion Criteria (Group 2)
* Age 18 to 50 years
* Male and Female
* Engaged in a minimum of 4 cumulative hours of moderate to vigorous intensity aerobic exercise, over a minimum of 3 days per week.
* BMI between 18 and 29.9 kg/m2
* VO2max \> 45 ml/min/kg BW
Non-diabetes Inclusion Criteria (Group 3)
* Age 30 to 65 …
What they're measuring
1
Change in ATPmax
Timeframe: Baseline and 10 weeks
Trial details
NCT IDNCT01911104
SponsorAdventHealth Translational Research Institute